CBG Cuts Rheumatoid Arthritis Inflammation by Up to 98%, New Study Finds

A preclinical study from researchers at the Rambam Health Care Campus in Haifa, Israel has found that cannabigerol — better known as CBG — directly suppresses the immune-cell signaling that drives rheumatoid arthritis, with reductions in key inflammatory cytokines reaching 98 percent in some measurements. Published in the journal Pharmaceuticals and circulating widely in 2026, the work positions CBG as a non-intoxicating cannabinoid candidate for a disease that affects more than 18 million people worldwide and still lacks a therapy that targets the neutrophil pathway directly.

The findings extend a growing body of cannabinoid research into rheumatology and arrive at a moment when patients, clinicians, and biotech investors are paying closer attention to minor cannabinoids beyond THC and CBD.

What CBG Is and Why It Matters

Cannabigerol is one of more than 100 cannabinoids the cannabis plant produces. Often called the "mother cannabinoid," CBG is biosynthetically the precursor to THC, CBD, and CBC — meaning the plant builds the better-known molecules from CBG as it matures. Mature flower typically contains less than 1 percent CBG by weight, which is why CBG products were rare and expensive until breeders began developing high-CBG cultivars in the early 2020s.

Unlike THC, CBG does not produce intoxication. It has a relatively weak affinity for the CB1 cannabinoid receptor that drives the THC high, but it interacts with a broader set of targets including alpha-2 adrenergic receptors, 5-HT1A serotonin receptors, and TRPA1 — all of which have known roles in pain and inflammation. That mechanistic breadth is part of what makes CBG attractive as an anti-inflammatory candidate.

The Rambam Study Design

The Rambam team set out to test CBG against rheumatoid arthritis (RA) using two complementary models. The first was ex vivo: human neutrophils isolated from blood samples were exposed to CBG and then challenged with inflammatory triggers. The second was in vivo: laboratory mice with induced arthritis received CBG and were tracked for disease progression, joint inflammation, weight, and cytokine levels.

Neutrophils are a type of white blood cell that play a foundational role in RA. In a healthy immune response, neutrophils migrate to sites of infection and release defensive compounds. In RA, that same machinery turns against the body — neutrophils flood synovial joints, release damaging proteases and reactive oxygen species, and amplify the cytokine cascade that destroys cartilage and bone over time. Despite decades of RA drug development, no approved therapy directly targets the neutrophil pathway.

Key Numerical Results

The numbers reported in the study are striking, particularly for a preclinical paper. In ex vivo testing on isolated human neutrophils, CBG reduced secretion of tumor necrosis factor alpha (TNF-α) by 68 percent and interleukin-6 (IL-6) by 72 percent in a dose-dependent manner. Both cytokines are central drivers of RA inflammation and are the targets of expensive biologic drugs such as adalimumab and tocilizumab.

In the mouse joints, CBG was associated with even larger reductions: IL-6 dropped by 98 percent and interleukin-1 beta (IL-1β) fell by 60 percent. The chemokine MCP-1, which recruits monocytes to inflamed tissue, decreased by 22 percent. A separate measurement of IL-1β in the joint environment showed a 38 percent reduction.

Mice treated with CBG also had improved arthritic scores — a standard composite that tracks joint swelling, redness, and impaired movement — and were less likely to experience the weight loss that typically accompanies active RA in animal models. The disease still appeared in treated mice, but in a less severe form.

Why the Mechanism Is Different

Most modern RA therapies are biologics that bind specific cytokines after they have been released, neutralizing them in circulation. TNF-α inhibitors, IL-6 inhibitors, and JAK inhibitors all work downstream of the cell-signaling events that produced the cytokines in the first place.

CBG appears to work earlier in the cascade. The Rambam authors describe CBG as directly regulating the white blood cells — the neutrophils — that release those cytokines. By making it less likely that neutrophils will respond to an inflammatory signal and migrate toward the joint, CBG addresses the upstream behavior that creates the cytokine flood in the first place.

That upstream positioning is important for two reasons. First, it suggests CBG could potentially complement, rather than replace, existing biologics. Second, it provides a mechanistic explanation for why CBG might affect multiple cytokines at once — because it is acting on the cell that produces them, not on any single downstream messenger.

Limits and Context

The study is preclinical. Ex vivo data and mouse models do not always translate to human disease, and rheumatology has a long history of compounds that looked promising in animals and underperformed in clinical trials. CBG's path from this study to an approved therapy would involve dose-finding, safety pharmacology, and at least three phases of human trials — typically a decade-plus journey.

The 98 percent IL-6 reduction in mouse joints should also be read in context. Animal models of arthritis can produce dramatic single-cytokine effects that look smaller in heterogeneous human disease. The more conservative ex vivo numbers — TNF-α down 68 percent, IL-6 down 72 percent in human cells — are likely a better guide to what realistic human dosing might produce.

CBG is also still a relatively expensive cannabinoid to produce at pharmaceutical purity. Costs are coming down as cultivation improves and biosynthetic production scales, but a finished CBG drug would compete with biologics that are themselves expensive but heavily insured.

What It Means for Patients Now

CBG products are widely available in legal cannabis markets and through hemp-derived channels, often as isolates, oils, or 1:1 blends with CBD. Patients should be clear-eyed about what this study does and does not support. It does not support self-medicating RA with over-the-counter CBG instead of prescribed therapy. It does support continued conversation with rheumatologists about cannabinoid options as adjuncts, and it strengthens the case for human trials of pharmaceutical-grade CBG in inflammatory conditions.

Anyone considering CBG for joint pain or inflammation should discuss it with a clinician, particularly if they are on immunosuppressive or biologic therapy, as cannabinoid–drug interactions remain an active research area.

Key Takeaways

• A 2026 Rambam Health Care Campus study published in Pharmaceuticals found that CBG suppresses neutrophil-driven inflammation central to rheumatoid arthritis.
• In isolated human neutrophils, CBG reduced TNF-α by 68 percent and IL-6 by 72 percent in a dose-dependent manner.
• In mouse joints, CBG cut IL-6 by 98 percent and IL-1β by 60 percent, with MCP-1 down 22 percent.
• The mechanism is upstream — CBG appears to regulate the immune cells that release inflammatory cytokines, rather than binding cytokines after release.
• No currently approved RA therapy directly targets the neutrophil pathway, making CBG a potentially novel therapeutic angle pending human trials.

Explore cannabis news, find dispensaries, and join the community at Budpedia.